Bharat Biotech ties up with Ocugen for Covaxin manufacture, sale in Canada

Ocugen Inc. and Bharat Biotech on Thursday (June 3, 2021) announced that they have entered into an amendment to their Co-development, Supply, and Commercialization Agreement to expand Ocugen's exclusive territory to commercialize Covaxin.

New Delhi: Hyderabad-based Bharat Biotech on Thursday (June 3, 2021) said that biopharmaceutical company Ocugen Inc will have exclusive co-development, manufacturing, and commercialisation rights of its COVID-19 vaccine Covaxin in Canada, in addition to its existing United States rights. According to the Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen Dr Shankar Musunuri, Covaxin is yet to get approval for emergency use in the US and Canada. "Ocugen Inc. and Bharat Biotech today announced that they have entered into an amendment to their Co-development, Supply, and Commercialization Agreement to expand Ocugen's exclusive territory to commercialize Covaxin to now also include Canada, in addition to Ocugen`s existing rights to commercialize Covaxin in the United States," said a joint statement by both companies. Dr Shankar Musunuri said that this amendment to expand his company’s rights to commercialise Covaxin into Canada speaks to its strong relationship with Bharat Biotech and joint dedication of both companies to bring vaccine to additional countries.